jetcityimage/iStock Editorial via Getty Images Eli Lilly ( LLY ) said its targeted cancer therapy Retevmo significantly reduced the risk of disease recurrence or death in patients with early-stage RET fusion-positive non-small cell lung cancer, according to results from a Phase 3 clinical trial presented Sunday at the American Society of Clinical Oncology annual meeting and published simultaneously in the New England Journal of Medicine . The study, known as LIBRETTO-432, evaluated Retevmo (selpercatinib) as an adjuvant treatment following surgery or radiation in patients with stage IB-IIIA RET fusion-positive NSCLC. Lilly said the trial met its primary endpoint, with the treatment reducing the risk of recurrence or death by 83% compared with placebo. Among patients with stage II-IIIA disease, event-free survival was significantly longer for those receiving selpercatinib. At 24 months, 92% of patients treated with the drug remained event-free, compared with 61% of those receiving placebo. The median event-free survival had not yet been reached in the treatment group, versus 31.8 months for placebo. Results were similar across the broader study population, which included patients with stage IB disease. In that group, the 24-month event-free survival rate was 94% for patients receiving selpercatinib and 70% for those receiving placebo. The trial enrolled 151 patients globally and randomized them to receive either selpercatinib or placebo for up to three years following curative-intent treatment. Jonathan Goldman, director of clinical trials at the University of California, Los Angeles, said the findings could influence treatment practices for patients with RET-positive lung cancer and highlighted the importance of genomic testing at diagnosis. The safety profile was generally consistent with prior studies of the drug. The most common severe adverse events involved elevated liver enzymes, including alanine aminotransferase and aspartate aminotransferase, which Lilly sa...

Nvidia owns a small group of stocks.

Key PointsWhile Nvidia's main business is designing chips and other artificial intelligence infrastructure, it also invests some of its capital in public and private companies.

Rob Wilkinson/iStock via Getty Images Intellia Therapeutics Investment Overview In February I wrote a post for Seeking Alpha on the gene therapy-focused biotech Intellia Therapeutics ( NTLA ), titled "2 Major Catalysts Will Determine Stock's Trajectory In 2026." At the time of publication, Intellia stock traded at $11.1 per share, and at the time of writing, it is up >25%, trading at $14 per share, with a market cap valuation of $1.96bn. What were the two catalysts? First of all, let's consider Intellia's current drug development pipeline, shown below (slide taken from a May 2026 corporate presentation ): Intellia - pipeline overview (presentation) Although CRISPR Therapeutics ( CRSP ) and partner Vertex ( VRTX ) were the first to secure an approval for a CRISPR/Cas9 gene-editing drug (a naturally occurring genome editing system adapted to make precise cuts in genes and leverage their repair mechanism to add, delete, or change the DNA sequence), Casgevy, indicated for Sickle Cell Disease ("SCD") and Beta Thalassemia ("TDT"), is an ex vivo drug, i.e., the patient's cells must be extracted, engineered in a lab, and reinfused back into the patient. Ex vivo treatment is a long and complex process, but Intellia is attempting to score a historic first approval for an in vivo CRISPR drug, i.e., one that can be administered via a short infusion at a Physician's office, potentially capable of providing a "functional cure" for a disease (as Casgevy does for SCD and TDT). As such, the readout of Phase 3 data for Intellia's hereditary angioedema ("HAE") candidate lonvoguran ziclumeran ("lonvo-z") due "mid-2026" was the first major catalyst I highlighted for 2026. Lonvo-Z Data Fails To Wow Market But Could Still Lead To Approval Intellia duly reported its Phase HAE study data on April 27th, which triggered a dip in the stock price, which fell from $16.5 per share to ~$12.5 - a drop of ~24%. In its press release, Intellia first notes that: HAE is a rare genetic condition in which...

Immigrant Hordes Set Paris Ablaze Because Their Soccer Team Won In case you needed further justification for denying your woman's request for a vacation in Paris, hordes of migrants gave your position another boost over Saturday night , as they rampaged across the "City of Light" and other French locales, setting structures and vehicles ablaze, smashing the windows of occupied cars, destroying shops and unleashing other varied forms of mayhem. And they were doing this because they were happy...about a soccer game . La Tour Eiffel est noyée sous un nuage de fumée après un départ de feu sur les quais de seine. Situation toujours très tendue dans ce secteur. #PSG #PSGARS #Arsenal #UCLfinal #Paris pic.twitter.com/89XVXjfRho — Luc Auffret (@LucAuffret) May 31, 2026 Yes, attacking French society (such as it is) was the outlet for joy they felt over Paris Saint-Germain (PSG) defeating the London-based Arsenal soccer team via a penalty shootout in the Champions League final. After the game, they poured into the streets and began destroying other people's property. 🇫🇷 Paris currently looks like a war zone. Again. North African gangs are blocking the streets and destroying everything in sight following PSG winning the Champions League. Total chaos. pic.twitter.com/pzRsF0iXX7 — Dr. Maalouf ‏ (@realMaalouf) May 30, 2026 Police deployed tear gas in clashes around Paris. More than 400 people were arrested across France by Sunday's early hours, including at least 280 in Paris, according to the French interior ministry. Seven police officers were injured . Last year's PSG championship also sparked disaster, including the death of a 17-year-old. The situation is worsening and getting completely out of control in Paris. The Champs-Élysées area is being destroyed, with migrant gangs reportedly even attempting to set fire to the Arc de Triomphe. A literal war zone. pic.twitter.com/yENmLrpRXm — Dr. Maalouf ‏ (@realMaalouf) May 30, 2026 "Only in France does a football club's victory spar...

柬埔寨前工业、矿产与能源部部长，柬埔寨区域研究中心杰出高级顾问波·索提拉克5月31日在新加坡举行的第23届香格里拉对话会期间接受记者采访时说，不认同美国所谓“以备战求和平”的理念，依靠军事力量或实力优势所维系的和平不可持续。索提拉克说，美国有句话——“如果你想要和平，就必须为战争做好准备”，这并不是一个好的建议。“如果你通过军事力量、军事能力或者实力优势来寻求和平，那么这种和平不是可持续的。”他强调，真正的和平应建立在对话、外交与相互理解的基础之上。（新华社）

一项最新调查结果显示，今年6月，日本市场将有超过1000种食品价格上涨。按日本媒体说法，受中东局势影响，原材料和包装材料等成本攀升，预计日本今后数月食品涨价势头将持续。（新华社）

科技基金业绩大分化，重仓AI算力年内浮盈近翻倍，不在“光”里的反亏逾25% 科技行情持续火爆，但相关基金净值却演绎着截然不同的故事。 一方面，重仓光模块、PCB（印制电路板）、芯片存储等AI算力相关资产的产品年内收益逼近翻倍；另一方面，部分科技基金却陷入亏损泥潭，这些重仓AI应用、软件、游戏、港股互联网的基金明显掉队。 第一财经据Wind统计，截至5月29日，在151只（仅统计主代码）名称中带“科技”的主动权益基金中，131只年内收益为正，其中有45只产品年内收益超过50%，11只甚至突破70%。但仍有20只不涨反跌，收益告负，首尾收益差距约115个百分点。 当基民在社区调侃“误以为自己站在光里”时，一个尖锐的问题浮出水面：当前极致火热的科技行情，究竟还能延续多久？ 赢家站在“光里” 具体看，近一个月来，A股科技成长赛道成为市场投资主线。申万一级行业中，近一个月涨势最好的是电子行业，涨幅达到24.89%；通信行业指数位居第二，区间涨幅为20.13%。 重仓CPO（共封装光学）、PCB、芯片存储等高景气细分赛道的基金产品净值水涨船高。5月以来，上述统计样本中，有23只科技基金净值涨幅突破20%。中海科技创新上涨30.29%，大成科技创新上涨29.39%，此外，还有21只基金同期净值涨幅超20%。 从更长时间维度看，年内收益率超过70%的主动权益基金有11只，平安科技精选为90%，排在首位，红土创新新科技、财通科技创新、红土创新科技创新收益率均超80%。 从重仓方向看，这些基金一季度末重仓股均聚焦5G、光模块、半导体存储、芯片方向。其中，根据一季报重仓持股数据，平安科技精选持仓市值最多的个股分别是长芯博创、新易盛、中际旭创、莱特光电、斯迪克、长飞光纤。 同样叫“科技基金”，有些基金的净值表现却明显掉队。上银科技先锋、鹏华科技驱动、湘财科技智选、华泰柏瑞科技创新、交银科技创新年内净值跌超10%。分别为-25.3%、-17.6%、-12.3%、-10.39%、-10.16%。 在重仓行业上，这部分科技基金今年以来重点买入的是游戏传媒、AI应用、软件服务、机器人及智能制造等方向，其中，上银科技先锋一季度重仓股集中在吉比特、世纪华通、巨人网络、三七互娱、腾讯控股、哔哩哔哩等游戏及互联网内容公司，年内净值跌幅超25%，目前在统计样本中亏损最多。 鹏华科技驱动则重仓网宿科技、顺网科...

Are Micron and Sandisk Stocks in a Bubble? AOL.com

Key PointsSocial Security beneficiaries may want to work to supplement their checks.

(RTTNews) - Pfizer Inc. (PFE) announced detailed progression-free and overall survival results from Cohort 3 of the Phase 3 BREAKWATER trial. This randomized cohort evaluated BRAFTOVI (encorafenib) in combination with cetuximab (ERBITUX) and FOLFIRI (fluorouracil, leucovorin, and

MONGBWALU, DEMOCRATIC REPUBLIC OF CONGO - MAY 21: An aerial view of artisanal mining sites, the General Referral Hospital of Mongbwalu and parts of the on May 21, 2026 in Mongbwalu, Democratic Republic of Congo. The World Health Organization (WHO) has declared the Ebola outbreak in the Democratic Republic of Congo (DRC) and Uganda a "public health emergency of international concern," as the death toll and number of confirmed cases continue to rise. The current epidemic is caused by the Bundibugyo virus, one of several Orthoebolaviruses that can cause Ebola disease, and for which there are no approved vaccines. The highest number of cases have been reported in Congo's eastern Ituri province, bordering Uganda. Global health officials have expressed grave concern over the capacity to contain the outbreak in a region already facing a humanitarian crisis, with highly mobile populations displaced by conflict and economic factors. (Photo by Michel Lunanga/Getty Images) Photographer: Michel Lunanga/Getty Images Europe

Mizuho Securities Maintains Advanced Micro Devices(AMD.US) With Buy Rating, Raises Target Price to $615 富途牛牛

MicroStockHub/iStock via Getty Images IUSV Strategy The iShares Core S&P U.S. Value ETF ( IUSV ) was launched on 7/24/2000 and tracks the S&P 900 Value Index. IUSV has a portfolio of 742 stocks, a 30-day SEC yield of 1.79%, and an expense ratio of 0.04%. Distributions are paid quarterly. As described by S&P Global , S&P 900 stocks are classified in "Value" and "Growth" styles using a ranking system based on three valuation ratios and three growth metrics. The valuation ratios are book value to price, earnings to price, and sales to price. By construction, 33% of S&P 900 constituents exclusively belong to each style, and 34% belong to both styles. The "Value" style subset defines the S&P 900 Value Index. It is capital-weighted, with an adjustment for constituents belonging to both styles. These stocks get a higher weight in the value index than in the growth index when their value rating is higher than their growth rating, and the other way around. The index is reconstituted annually and rebalanced quarterly. The portfolio turnover rate was 31% in the most recent fiscal year. I will use the iShares Russell 1000 ETF ( IWB ) as a benchmark. Portfolio IUSV invests almost exclusively in U.S. companies (99% of asset value), with a tilt to large and mega-caps (about 62%). Although the fund greatly downplays information technology and communication services compared to the benchmark, technology still is the heaviest sector (20.1%), followed by financials (15.3%). IUSV sector breakdown (Chart: author; data: iShares) Concentration in the top 10 holdings is moderate (23.3% of asset value, as listed below), but the portfolio has notable company-specific risk (7.4% in Apple). Ticker Name Sector Weight% AAPL APPLE INC. Information Technology 7.44 AMZN AMAZON.COM INC. Consumer Discretionary 4.08 XOM EXXON MOBIL CORP. Energy 1.99 INTC INTEL CORPORATION Information Technology 1.84 WMT WALMART INC. Consumer Staples 1.69 TSLA TESLA INC. Consumer Discretionary 1.53 COST COSTCO WHOLESAL...

5月31日，缅甸掸邦北部南坎镇发生一起爆炸事故，已导致多人伤亡，多处民宅、房屋遭到严重损毁。经初步调查，此次事故为炸药爆炸引起，爆炸地点存储着大量用于采矿作业的炸药。目前当地相关部门正对受灾民众开展救济、医疗和安置工作。（央视新闻）

格隆汇5月31日｜据英国金融时报，非洲疾控中心官员表示，截至5月30日，刚果（金）和乌干达已报告263例埃博拉确诊病例，其中包括43例死亡病例。

This highly focused healthcare company has seen its shares fall 30% in 2026 despite still strong business growth.

Key PointsIntuitive Surgical is a leader in robotic surgery.

Steve Jobs' Secret To Hiring Apple's Top Talent - Apple (NASDAQ:AAPL), Tesla (NASDAQ:TSLA) Benzinga

'You Don't Need A 10-Year Plan,' Former Meta Operating Chief Tells Gen Z To Abandon Age-Old Career Advice Benzinga

In this article RVMD Follow your favorite stocks CREATE FREE ACCOUNT Pancreatic cancer, illustration Nemes Laszl | Science Photo Library | Getty Images A novel pill helped people with advanced pancreatic cancer live longer, researchers reported Sunday, raising hopes of long-needed better treatments for one of the deadliest types of cancer. "While not curing the cancer, it is a very large step forward," said Dr. Zev Wainberg, of the University of California, Los Angeles, who helped lead the study. The drug is called daraxonrasib, and it blocks a mutated protein that fuels tumor growth in more than 90% of pancreatic cancer cases — a target that had eluded treatment for decades. The daily pills nearly doubled survival time, with fewer severe side effects, in a study that randomly assigned the experimental drug or more chemotherapy to 500 patients whose metastatic, or spreading, cancer had quit responding to prior treatment. The findings were published in the New England Journal of Medicine and presented Sunday at the American Society for Clinical Oncology meeting in Chicago. Those taking daraxonrasib lived for a median of 13.2 months compared with 6.7 months for chemotherapy recipients. While that may seem like a small improvement, Wainberg said it marked the first drug to show a substantial advantage over chemotherapy. "Having treated pancreatic cancer for 16 years, I actually started crying" when first seeing the study results, Dr. Rachna Shroff of the University of Arizona Cancer Center, who wasn't involved with the research, said from the ASCO meeting. She was struck by how "patients stayed on this treatment because it was providing durable and meaningful benefit to them." The pills' effects eventually wane, but recipients used them for significantly longer than the comparison group stayed on chemotherapy, reporting less pain and a better quality of life as their tumors shrank. Many still were using the drug after the data was analyzed, which Wainberg said means th...

Micron, SanDisk get a number Wall Street rarely writes thestreet.com

5月31日，在2026世界超级摩托车锦标赛（WSBK）西班牙阿拉贡站WorldSSP组别第二回合正赛中，中国摩托车制造商“张雪机车”旗下的法国车手瓦伦丁·德比斯在激烈角逐中获得第8名。（央视新闻）

On the fringes of Israel's far right, some activists and political leaders dream of a Greater Israel, extending the country's borders into neighboring countries.

Sun Tzu wrote that “fighting and winning all your battles is not the height of skill; subduing the enemy without fighting is the height of skill”. That maxim offers perhaps the clearest lens to interpret the logic of American grand strategy under US President Donald Trump. What many dismiss as inconsistency may conceal a patient strategic deception. The aim is not direct confrontation, but the quiet reshaping of the global economy in support of long-term US power. The US wants to improve its...

Time for some stock splits!

There’s so much cash going to emerging markets that a pair of hedge funds that specialize in hard-to-reach debt are starting to turn away investors. Shiprock Capital Management Ltd. , which invests in distressed debt of Venezuela, Argentina and Ukraine, is saying no to new cash after assets under management topped $1 billion. Managers at Broad Reach Investment Management , a $3 billion firm, say they will look to close their main fund once they reach their AUM ceiling later this year. Both firms are reaping the rewards of rapid growth, but all that extra money means it’s getting harder to deploy funds in small markets without moving prices and big positions can be difficult to unwind. With more cash chasing a small pool of assets, it’s tougher for funds to beat their benchmarks, money managers say. “You still want to be nimble — you still want to be able to buy and trade and remain liquid,” said Frederick Schroder , chief executive officer at Shiprock Capital. “Infinite capital is not your friend in the space.” Against a backdrop of soaring bond yields from the US, UK and Japan, EM debt funds are drawing investors looking for an alternative. Developing-nation debt posted its seventh week of inflows at $3.1 billion in the period to May 27, according to Bank of America, which cited EPFR Global data . It’s a similar story over at Sandglass Capital Management Ltd. , another EM distressed debt specialist. The firm’s managers say they’re being more selective after assets under management jumped to $1 billion, from about $600 million a year ago. ‘Niche Markets’ Evgueni Konovalenko , managing partner and head of strategy & business development at ProMeritum Investment Management, whose AUM surpassed $1 billion at the start of February, cites the example of an investment in Uganda which eventually accounted for 3% of his portfolio. “Because we manage a $1.1 billion fund, we cannot scale that position further,” he said. “Small, niche markets like Uganda simply lack the depth ...

Jonathan Kitchen/DigitalVision via Getty Images Article Thesis Semiconductor stocks have done very well so far this year, and recent 13-F filings show that many large investors have added to their positions in a broad range of semiconductor stocks. But does that mean that buying into these chip players at current prices and valuations is a great idea? In this article, I will lay out why I believe that some semiconductors are overbought and too expensive – and why I believe that some software plays are quite attractive today, even though they get less attention. Past Coverage I have written about many chip and software stocks here on Seeking Alpha in the past, such as this recent NVIDIA ( NVDA ) article and this Buy-rating Taiwan Semiconductor Manufacturing Company ( TSM ) article from April – TSM has delivered gains of 12% since then. Other articles on chip and software stocks include Adobe ( ADBE ), Advanced Micro Devices ( AMD ), and so on, which you can find via my profile page if interested. Not All Tech Stocks Are Created Equal The broad equity markets have done quite well over the last couple of years, with major indices hitting new all-time highs this year. This is especially true for the tech-heavy NASDAQ index ( NDX )( QQQ ), as we can see in the following chart: Data by YCharts The NASDAQ has delivered more than 40% over the last year, with a lot of that coming over the last two months or so. That's also when most of the outperformance versus the S&P 500 ( SPY ) and the Dow Jones ( DIA ) was created. But while the NASDAQ has delivered a very strong performance of more than 40% over the last year, there are large divergences when it comes to the different parts that make up the tech index. Some sub-sectors did a lot better than others, with semiconductors/chips and software being especially noteworthy: Data by YCharts The VanEck Semiconductor ETF ( SMH ) has returned close to 70% this year alone and is up way over 100% over the last 12 months, while the iSh...